



Tryp Therapeutics Inc

Symbol: CSE: TRYP | OTCQB: TRYPF

Market Cap: 23M

Sector: Mushroom | Biotech

Purpose: Market Awareness / Open Market Buying

Website: www.trypterapeutics.com.

Tryp Therapeutics is leading the next wave of psychedelic drug development beyond mental health with its focus on chronic pain and other indications. Tryp is on the cusp of initiating four Phase 2a clinical trials using synthetic psilocybin for fibromyalgia, phantom limb pain, complex regional pain syndrome (CRPS), and certain overeating disorders representing more than \$12 billion in potential annual sales potential. The company's Scientific Advisory Board is chaired by Robin Carhart-Harris, one of the most prominent psychedelic researchers in the world.

INVESTOR BULLET POINTS

- Differentiated and highly valuable chronic pain and other indications representing more than \$12 billion in potential annual sales potential.
- Highly experienced management and scientific team that knows how to develop and obtain approval from the FDA for new drug products
- Significantly undervalued investment opportunity relative to other psychedelics at similar stages of development; Tryp is on the verge of initiating four Phase 2a clinical trials, a rare feat in the space.

[Presentation Link](#)

Greg McKee

Greg serves as Chairman and Chief Executive Officer of Tryp Therapeutics. He has served in executive management positions for more than 20 years. He started his career in life sciences with Genzyme before serving as Chairman and CEO of publicly traded Nventa Biopharmaceuticals. Greg also served as CEO of CONNECT, a startup accelerator, and as Co-founder and Managing Director of Torrent Ventures. Greg earned a BA in economics from the University of Washington, an MA in international studies from the University of Pennsylvania and an MBA from the Wharton School. He has worked in Tokyo for seven years and has been a member of YPO since 2006.